^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | pegylated liposomal doxorubicin (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
HER2 Negative Breast Cancer:…Invasive Breast Cancer…SYSTEMIC THERAPY REGIMENS FOR RECURRENT OR STAGE (IV) M1 DISEASE…HER2-Negative…Preferred Regimens…Anthracyclins…Liposomal doxorubicin
Source:
Title:
Clinical Study of Pegylated Liposomal Doxorubicinin and Sintilimab plus Anlotinib in Patients with Advanced Triple-Negative Breast Cancer
Excerpt:
......
Trial ID:
Source:
Title:
Clinical trial to evaluate the feasibility of pegylated liposomal doxorubicin (Caelyx¿) in women operated for a breast cancer with estrogen receptors expression but either high proliferation rate, or low progesterone receptors expression, or overexpression of HER2. Studio che valuta la fattibilit¿ di una chemioterapia con doxorubicina liposomale pegilata (Caelyx¿) in donne operate per un tumore mammario che esprime i recettori per gli estrogeni ma che presenta o una elevata proliferazione del tumore o una ridotta espressione dei recettori per il progesterone, o che sovra-esprime il recettore HER2
Excerpt:
...• Operable histologically confirmed breast cancer • Luminal B HER2-negative (ER positive, HER2 negative, and at least one of the following: Ki-67 ‘high’ (=20%) or PgR ‘negative or low’) or Luminal B HER2-positive (ER positive, HER2 over-expressed or amplified, any Ki-67, any PgR)• Early-stage (pT1-3; any nodal status) • Candidate to adjuvant chemotherapy and endocrine therapy• The tumor must be confined to the breast and axillary nodes without detected metastases elsewhere• Patients with synchronous (diagnosed histologically within 2 months) bilateral invasive breast cancer are eligible if all other criteria are met• Patients must have had surgery for primary breast cancer with no known clinical residual loco-regional disease• Margins must be negative for invasive breast cancer and DCIS• Patients should be start treatment as close to definitive surgery as possible (no later than 8 weeks)• No prior neoadjuvant or adjuvant therapy for breast cancer. ...
Trial ID:
